Quarterly report pursuant to Section 13 or 15(d)

Fair Value of Financial Instruments (Tables)

v3.23.1
Fair Value of Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Our financial instruments measured at fair value on a recurring basis were as follows at the dates indicated:

Condensed Consolidated
Balance Sheet Caption
Fair Value at March 31, 2023
(in thousands) Level 1 Level 2 Level 3 Total
Liabilities:
Contingent consideration - current Accrued expenses and other current liabilities —  —  2,738  2,738 
Total Liabilities $ —  $ —  $ 2,738  $ 2,738 
Consolidated
Balance Sheet Caption
Fair Value at December 31, 2022
(in thousands) Level 1 Level 2 Level 3 Total
Liabilities:
Contingent consideration - current Accrued expenses and other current liabilities $ —  $ —  $ 2,738  $ 2,738 
Total Liabilities $ —  $ —  $ 2,738  $ 2,738 
Schedule of Fair Value, Liabilities Measured on Recurring Basis
A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:
(in thousands) Three months ended
March 31, 2023
Balance at December 31, 2022 $ 2,738 
Loss (gain) from fair value adjustments included in results of operations — 
Balance March 31, 2023 $ 2,738 
(in thousands) Three months ended
March 31, 2022
Balance at December 31, 2021 $ 6,857 
Eyce 2021 Contingent Payment settlement in Class A common stock (875)
DaVinci 2021 Contingent Payment settlement in Class A common stock (2,611)
Gain from fair value adjustments included in results of operations (5)
Balance March 31, 2022 $ 3,366